Ahmed Smman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ahmed Smman has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Ahmed Shahin
Cardiology Department, Hampshire Hospitals NHS Foundation Trust, Basingstoke RG24 9NA, UK
2 shared publications - Luciano Candilio
Cardiology Department, Royal Free London NHS Foundation Trust, London NW3 2QG, UK
2 shared publications - Ramy Kishk
Cardiology Department, Royal Free London NHS Foundation Trust, London NW3 2PS, UK
2 shared publications - Salaheldin Agamy
Cardiology Department, University Hospitals Birmingham NHS Foundation Trust, Birmingham B15 2GW, UK
2 shared publications - Sheref Zaghloul
Cardiology Department, Royal Berkshire Hospital, Reading RG1 5AN, UK
2 shared publications - Zahid Khan
Townsville University Hospital, Townsville, Australia
2 shared publications
Latest Publications
- Open Access
- 27 December 2025
- Published by MDPI AG in Diagnostics
- Vol. 16 (1) , 98
Innovations in Diagnosis and Treatment of Coronary Artery Disease
Background: Coronary artery disease (CAD) remains a significant health challenge, placing a heavy burden on people and healthcare systems worldwide. Objectives: This narrative review aims to provide a comprehensive overview of recent advancements in the diagnosis, intervention, and pharmacological management of CAD, with a focus on emerging technologies shaping its future. Methods: This is a narrative review that synthesises information from diverse sources, including clinical trials, systematic reviews, meta-analyses, and preclinical studies, to provide a comprehensive overview of the current landscape and emerging trends in CAD management. The literature included in this review was sourced from original research articles and review papers published between January 2010 and December 2025. Results: Early detection has been transformed by non-invasive imaging, such as PCAT, and the addition of invasive and non-invasive FFR technology enables quicker and more accurate diagnoses. Biomarkers, such as high-sensitivity troponin, have further improved the precision of acute coronary syndrome detection, enhancing early intervention. In interventional cardiology, new-generation drug-eluting stents (DESs) have lowered restenosis rates, whereas robotic-assisted percutaneous coronary intervention (PCI) offers precision and reduced operator radiation exposure. Furthermore, the efficacy of drug-coated balloons (DCBs) has been established in the management of in-stent restenosis, and their application in de novo coronary lesions and bifurcation anatomy remains promising. Looking ahead, nanomedicine promises targeted plaque reduction and vascular repair, while 3D-bioprinted blood vessels offer durable, biocompatible grafts for surgical applications. Pharmacological developments, including modern cholesterol-lowering drugs, have also been crucial in achieving cholesterol targets. Conclusions: Despite significant advancements in diagnosis, intervention, and pharmacotherapy, several critical challenges remain, including the need for validated biomarkers and imaging modalities to identify vulnerable atheroma before symptoms arise. Continued research is essential to improve patient outcomes and address the global burden of CAD.
- 27 December 2025
- Published by MDPI AG in Diagnostics
- Vol. 16 (1) , 98
Open AccessInnovations in Diagnosis and Treatment of Coronary Artery Disease
Background: Coronary artery disease (CAD) remains a significant health challenge, placing a heavy burden on people and healthcare systems worldwide. Objectives: This narrative review aims to provide a comprehensive overview of recent advancements in the diagnosis, intervention, and pharmacological management of CAD, with a focus on emerging technologies shaping its future. Methods: This is a narrative review that synthesises information from diverse sources, including clinical trials, systematic reviews, meta-analyses, and preclinical studies, to provide a comprehensive overview of the current landscape and emerging trends in CAD management. The literature included in this review was sourced from original research articles and review papers published between January 2010 and December 2025. Results: Early detection has been transformed by non-invasive imaging, such as PCAT, and the addition of invasive and non-invasive FFR technology enables quicker and more accurate diagnoses. Biomarkers, such as high-sensitivity troponin, have further improved the precision of acute coronary syndrome detection, enhancing early intervention. In interventional cardiology, new-generation drug-eluting stents (DESs) have lowered restenosis rates, whereas robotic-assisted percutaneous coronary intervention (PCI) offers precision and reduced operator radiation exposure. Furthermore, the efficacy of drug-coated balloons (DCBs) has been established in the management of in-stent restenosis, and their application in de novo coronary lesions and bifurcation anatomy remains promising. Looking ahead, nanomedicine promises targeted plaque reduction and vascular repair, while 3D-bioprinted blood vessels offer durable, biocompatible grafts for surgical applications. Pharmacological developments, including modern cholesterol-lowering drugs, have also been crucial in achieving cholesterol targets. Conclusions: Despite significant advancements in diagnosis, intervention, and pharmacotherapy, several critical challenges remain, including the need for validated biomarkers and imaging modalities to identify vulnerable atheroma before symptoms arise. Continued research is essential to improve patient outcomes and address the global burden of CAD.
- Open Access
- 30 October 2025
- Published by MDPI AG in Preprints.org
Innovations of Diagnosis and Treatment of Coronary Artery Disease
Coronary artery disease (CAD) remains a significant health challenge, placing a heavy burden on people and healthcare systems worldwide. CAD is mainly caused by unstable plaque rupture, leading to acute coronary syndrome. Early detection has been transformed by non-invasive imaging, such as coronary CT angiography, and the addition of CT-FFR technology enables quicker and more accurate diagnoses. Biomarkers, such as high-sensitivity troponin, have further improved the precision of acute coronary syndrome detection, enhancing early intervention. In interventional cardiology, new-generation drug-eluting stents (DES) have lowered restenosis rates, whereas robotic-assisted percutaneous coronary intervention (PCI) offers precision and reduced operator radiation exposure. Furthermore, while the efficacy of drug-coated balloons (DCB) has been established in the management of in-stent restenosis, their application in de novo coronary lesions and bifurcation anatomy remains promising. Looking ahead, nanomedicine promises targeted plaque reduction and vascular repair, while 3D bioprinted blood vessels offer durable, biocompatible grafts for surgical applications. Pharmacological developments, including modern cholesterol-lowering drugs, have also been crucial in achieving cholesterol targets, as they have become even lower according to guidelines. Despite notable progress in coronary artery disease (CAD) management, clinical care remains reactive and often delays intervention until irreversible damage occurs, while economic burdens persist due to high treatment costs and productivity losses.
- 30 October 2025
- Published by MDPI AG in Preprints.org
Open AccessInnovations of Diagnosis and Treatment of Coronary Artery Disease
Coronary artery disease (CAD) remains a significant health challenge, placing a heavy burden on people and healthcare systems worldwide. CAD is mainly caused by unstable plaque rupture, leading to acute coronary syndrome. Early detection has been transformed by non-invasive imaging, such as coronary CT angiography, and the addition of CT-FFR technology enables quicker and more accurate diagnoses. Biomarkers, such as high-sensitivity troponin, have further improved the precision of acute coronary syndrome detection, enhancing early intervention. In interventional cardiology, new-generation drug-eluting stents (DES) have lowered restenosis rates, whereas robotic-assisted percutaneous coronary intervention (PCI) offers precision and reduced operator radiation exposure. Furthermore, while the efficacy of drug-coated balloons (DCB) has been established in the management of in-stent restenosis, their application in de novo coronary lesions and bifurcation anatomy remains promising. Looking ahead, nanomedicine promises targeted plaque reduction and vascular repair, while 3D bioprinted blood vessels offer durable, biocompatible grafts for surgical applications. Pharmacological developments, including modern cholesterol-lowering drugs, have also been crucial in achieving cholesterol targets, as they have become even lower according to guidelines. Despite notable progress in coronary artery disease (CAD) management, clinical care remains reactive and often delays intervention until irreversible damage occurs, while economic burdens persist due to high treatment costs and productivity losses.